

# **Appointment of Voluntary Administrators**

Sydney, Australia – 29 November 2023: At 12:14pm (AEDT) on 29 November 2023, the Board of Directors of Bod Science Limited ("Bod" or "the Company") (ASX: BOD) appointed Andrew Barnden and Brent Morgan (Administrators) of Rodgers Reidy as Joint and Several Administrators of the Company pursuant to section 436A of the Corporations Act 2001.

The Company's subsidiaries are not captured by the appointment of the Administrators.

#### Suspension of shares from trading whilst the Company is in Administration

Whilst the Company is in administration, all listed securities will remain suspended. Shareholders are also unable to transfer their shares during this time.

## **Current status of the Company**

The Administrators have assumed control of the Company's business and assets and will work with the Board of Directors during the administration period to maximise the outcome for all stakeholders of the Company.

### Updates on the progress of the Administration

The Administrators will provide updates of any material events throughout the administration by way of announcements to the ASX. The Administrators respectfully request that shareholders refrain from contacting the Administrators' office.

ASIC publishes Insolvency Information Sheets which provide information in relation to external administrations. Shareholders may obtain copies of these information sheets through the below link: <a href="https://asic.gov.au/regulatory-resources/insolvency/insolvency-information-sheets/">https://asic.gov.au/regulatory-resources/insolvency-information-sheets/</a>

This announcement has been approved by Andrew Barnden (Administrator)

-ENDS-

#### **About Bod Science:**

Bod Science (ASX: BOD) is a cannabis focused drug development and product innovation company.

Bod is focused on progressing research and development with a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for patients and consumers.

The company has a number of existing partnerships with large corporate companies and collaborations with leading research organisations to advance the use of Cannabis related medicines with therapeutic indications.

